<DOC>
	<DOCNO>NCT01050127</DOCNO>
	<brief_summary>The objective study assess safety , tolerability , pharmacodynamics pharmacokinetics multiple dos ABT-436 healthy adult .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Doses ABT-436 Healthy Adults</brief_title>
	<detailed_description />
	<criteria>1 . Age 18 55 year , inclusive . 2 . If female , subject must postmenopausal least two year surgically sterile . 3 . Females must negative result pregnancy test prior study drug administration . 4 . If male , subject must surgically sterile agree sexually inactive agree use barrier method birth control . 5 . Body Mass Index 18.0 29.9 kg/m2 ( 2 = superscript number ) , inclusive . 6 . A condition general good health base upon result medical history , physical examination , vital sign , laboratory profile , 12lead electrocardiogram . 7 . Must voluntarily sign date inform consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , prior initiation screen studyspecific procedure . 1 . History significant sensitivity allergy drug . 2 . Use known inhibitor inducer CYP3A within 30 day prior first dose study drug end study . 3 . Requirement , use within 2week period prior study drug administration , overthecounter prescription medication , vitamin , mineral herbal supplement regular basis . 4 . Receipt depot drug injection within 30 day prior study drug administration . 5 . Positive screen drug abuse alcohol , recent ( 6month ) history drug alcohol abuse . 6 . Use tobacco nicotinecontaining product within sixmonth period precede study drug administration . 7 . Donation loss 550 mL blood ( include plasmapheresis ) receipt transfusion blood product within 8 week prior first dose study drug . 8 . Receipt investigational product within time period equal 10 halflives , know , minimum 6 week prior study drug administration . 9 . Has clinically significant abnormal diastolic blood pressure ( &lt; 45 &gt; 90 mm Hg ) , systolic blood pressure ( &lt; 85 &gt; 140 mm Hg ) heart rate ( &lt; 45 &gt; 100 bpm ) . 10 . HbA1c &gt; 6.0 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Drug Safety</keyword>
	<keyword>Phase 1 Clinical Trial</keyword>
</DOC>